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Abstract 25 
Background: Lymphomas of the lacrimal sac are rare accounting for less than 10% of lacrimal sac malignant 26 
tumours.  They may present with symptoms typical of secondary acquired nasolacrimal duct obstruction and 27 
are thus often misdiagnosed. 28 
 29 
Methods: Case series and literature review. 30 
 31 
Results: Herein we describe 3 cases of chronic lymphocytic leukaemia (CLL)/small-cell lymphocytic 32 
lymphoma (SLL) of the lacrimal sac with immunohistochemical and in 1 case molecular confirmation. 33 
 34 
Conclusion: Lymphomas of the lacrimal sac should be suspected in patients with known CLL presenting 35 
with epiphora and dacryocystitis.  During dacryocystorhinostomy (DCR), an incisional biopsy of the lacrimal 36 
sac is essential for confirming CLL/SLL involvement and may guide treatment. 37 
 38 
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Malignant tumours of the lacrimal sac are uncommon with close to 90% of these being of epithelial origin.  40 
Lymphomas of the lacrimal sac are rare [1-3].  They may present with symptoms typical of secondary 41 
acquired nasolacrimal obstruction including epiphora with a medial canthal mass and thus often 42 
misdiagnosed.  It should be suspected in patients with known CLL presenting with epiphora and 43 
dacryocystitis.  During DCR an incisional biopsy of the lacrimal sac is essential for confirming CLL/SLL 44 
involvement and may therefore guide adjuvant treatment [1-7]. 45 
 46 
All patients had signed a written informed consent form and the study was conducted in accordance with the 47 
declaration of the Declaration of Helsinki. 48 
 49 
Case Reports 50 
Case 1: An 89 year-old male, with past medical history of CLL and left external DCR, presented to the eye 51 
department with a painful, discharging, cystic swelling in the right lacrimal sac area.  He was treated with 52 
antibiotics for his right-sided dacryocystitis, and later listed for a right external DCR.  Perioperatively, the 53 
lacrimal sac was noted to be inflamed, and hence an incisional biopsy taken.   54 
 55 
The specimen extended 8x5x3mm.  Histological examination revealed: a diffuse atypical lymphocytic 56 
infiltrate with mild nodularity; intermediate-sized cells with coarse nucleus and prominent nucleoli and large 57 
cells with prominent nucleoli in proliferation centres (Fig. 1A&B).  Ki67 immunostaining showed a 58 
moderate growth fraction with mitotic cells localized in proliferation centres (Fig. 1C).  Further evaluation 59 
with immunohistochemistry (IHC) confirmed monotypical B cells with positive staining for: CD5; CD20; 60 
CD23; CD79a; (Fig. 1D-F) BCL-2 with synthesis of IgM, IgD and equivalent staining of kappa and lambda 61 
light-chains, with a moderate background scattering of CD3+ T-cells.  The following immunostains were 62 
negative: cyclin-D1, CD21, CD10 and BCL-6.  Histological and IHC features were consistent with diffuse, 63 
well-differentiated CLL/SLL.  Immunoglobulin heavy-chain polymerase chain reaction (IgH-PCR) 64 
demonstrated a monoclonal B-cell population.  Furthermore, next generation sequencing was performed as 65 
previously described [8].  Briefly, target exons of 15 selected genes relevant to CLL were sequenced using 66 
Ion Torrent Personal Genome Machine (PGM) and Torrent Suite Pipeline v4 (Life Technologies, UK).  67 
Genes included were: TP53 (exons 2-11) and SF3B1 (exons 8-20); ATM (exons 2-63); MYD88 (exons 2-5); 68 
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BIRC3 (exons 2-9); NOTCH1 (exon 34); XPO1 (exons 11-16); LRP1B (exons 34-86); FBXW7 (exons 5-12); 69 
HIST1H1E (exon 1); ZFPM2 (exon 8); SAMHD1 (exons 1-16);  CHD2 (exons 12-36); POT1 (exons 5-19) 70 
and PCLO (exons 2-24).  This molecular panel has previously been reported to be associated with extensive 71 
nodal involvement indicating advanced stages of CLL and thus relevant for its prognosis [8].  Next 72 
generation sequencing was performed in this case to ascertain whether or not lacrimal sac involvement is 73 
associated with any of these gene mutations.  No somatic gene mutations were detected in the sample. 74 
     75 
The patient was already under the care of haematologists and had received chemotherapy – previous course 76 
of chlorambucil followed by bendamustine.  He was given a further single lower dose of bendamustine.  His 77 
lacrimal stents were removed 6 months post successful DCR and he was given a further 6 month follow up 78 
appointment.  Prior to his appointment at the eye department, the patient had surgery for a sebaceous cell 79 
carcinoma on his calf involving excision and grafting, which unfortunately failed and found to be infected 80 
with Pseudomonas.  He subsequently developed sepsis and was treated with intravenous antibiotics but 81 
rapidly deteriorated, and died within 4 days of admission. 82 
 83 
Case 2: A 66 year-old male, with known CLL in the past, presented with a 6 month history of epiphora and a 84 
painless hard mass over the right lacrimal sac.  Computed tomography revealed a soft tissue mass, measuring 85 
approximately 20x22x16mm, in the medial canthal region extending into the lacrimal fossa and nasolacrimal 86 
duct into the nasal cavity.  A right external DCR with an incisional biopsy of the lacrimal sac was performed.   87 
 88 
Histopathological analysis showed: a nodular and diffuse infiltration by intermediate-sized, round 89 
lymphocytes punctuated by pale-staining proliferation centres containing pro-lymphocytes and para-90 
immunoblasts.  There was an unusual degree of stromal fibrosis, marked perineural and perivascular 91 
sclerosis.  Tumour cells had a classical CLL phenotype: CD5+; CD20+; CD21+; CD23+; CD79a+; MUM-92 
1+ and BCL-2+ with synthesis of IgM.   CD3, CD10, cyclin-D1 and BCL-6 stains were negative.  The Ki-67 93 
growth fraction was <5%.  Plasma cells within sclerotic areas showed indeterminate light-chain staining.  94 
Overall, features were consistent with lacrimal sac involvement by SLL/CLL. 95 
 96 
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The patient had low-dose local radiation of the lacrimal sac area alone, as further disease was not detected 97 
elsewhere on staging.  The patient was re-referred to the eye department 2 years later for persistent epiphora 98 
secondary to post irradiation scarring.  There was a complete response locally but the patient suffered a 99 
relapse of the CLL elsewhere, received further chemotherapy, and was subsequently lost to follow up at the 100 
eye department. 101 
 102 
Case 3: A 75 year-old female, with a past medical history of: CLL (p53 deletion) treated with fludarabine 103 
and cyclophosphamide; successful left external DCR for recurrent dacryocystitis but local drainage of the 104 
right lacrimal sac due to relapse of her CLL, presented with a recent 6-month history of intermittent right eye 105 
epiphora.  Clinically there was right nasolacrimal duct obstruction but no palpable mass.  During external 106 
DCR, the right nasal process of frontal bone was noted to have a soft consistency with a spongy mucoid 107 
appearance and therefore prompted a biopsy.  There was no obvious tumour noted in the lacrimal sac. 108 
 109 
Histological assessment was limited due to a very small specimen and marked traction artefact.  Of note, 110 
however, small fragments of trabecular bone showed dense infiltration of the intratrabecular stroma by 111 
lymphoma (Fig 2A&B).  The tumour comprised small lymphocytes with scanty pale cytoplasm and small, 112 
round nuclei with condensed chromatin and no nucleoli.  The cell infiltrate were CD20+, CD79a+, CD5+, 113 
CD23+ (Fig 2C-E), BCL-2+, IgM+, IgD+ with kappa light-chain restriction; but negative for CD10, p53, 114 
MUM-1, CD43 and cyclin D1.  The Ki-67 growth fraction was <5%.  There was marked reduction of CD3+ 115 
and CD5+ reactive T-cells.  Histological and IHC appearances were consistent with involvement by 116 
SLL/CLL. 117 
 118 
The patient was referred back to haematologists and treated with chlorambucil and ofatumumab.  She has 119 
been in remission for 5 years. 120 
 121 
Discussion 122 
Lymphomatous involvement of lacrimal sac may be primary or secondary.  There are <70 primary cases and 123 
few case reports/series of secondary involvement.  Previous reporting would have been variable due to lack 124 
of global consensus regarding lymphoma classifications until the Revised European-American Classification 125 
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of Lymphoid Neoplasms, the WHO classification, and later the EORTC ophthalmic oncology task force 126 
study defining the clinical and histopathological characteristics [1-3, 9-10].  From the EORTC study of 15 127 
primary lacrimal sac lymphoma cases, 33% of cases were classified as diffuse large B cell lymphoma 128 
(DLBCL; non-Hodgkin’s lymphoma), 33% as extranodal marginal zone B cell lymphoma of mucosa 129 
associated lymphoid tissue (MALT lymphoma), 20% were classified as transitional MALT lymphoma with 130 
features between MALT lymphoma and DLBCL, and 13% as unclassified B cell lymphomas [10].  Of the 131 
other in the literature, it appears that DLBCL and MALT lymphomas occur with approximately equal 132 
frequency [1-3, 5, 7, 9-11].  However, DLBCL has been more frequently described in association with 133 
systemic lymphoma [2-3, 7].   134 
 135 
Lymphomas account for ~2-6% of lacrimal sac malignant tumours, present in generally older patients with 136 
symptoms typical of secondary acquired nasolacrimal obstruction including epiphora, medial canthal mass; 137 
thus often misdiagnosed as acute or chronic dacryocystitis [4-7].  It should be suspected in patients with 138 
known CLL presenting with epiphora and dacryocystitis.  DCR with stenting is well-tolerated and effective 139 
at alleviating symptoms.  During DCR an incisional biopsy of the lacrimal sac is essential for confirming 140 
CLL/SLL involvement, even in the absence of obvious swelling (as in 1 of our cases), and may guide 141 
adjuvant chemo- and/or radiotherapy treatment [1-4, 6].  Treatment is usually a combination of surgery, 142 
irradiation and /or chemotherapy (notably regimens involving chlorambucil) but no commonly agreed 143 
treatment regimen for periocular lymphoma exists because of the limited number of patients seen [2-3, 7, 10-144 
11]. 145 
 146 
In keeping with earlier reports [2-3], our patients had systemic CLL with secondary lacrimal sac infiltration, 147 
were elderly but one had presumed bilateral involvement (2 DCRs) and one with bony destruction which are 148 
rare.  Two of the patients had been treated with chemotherapy (including chlorambucil) whilst one had low-149 
dose local area irradiation as no further disease was detected.   150 
 151 
In summary, CLL/SLL infiltration of the lacrimal sac is rare and should be suspected in any patient with 152 
systemic CLL presenting with epiphora and/or lacrimal sac area mass.  Herein we present 3 cases with 153 
immunohistochemical confirmation and one where molecular testing was available – which, to our 154 
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knowledge, has not been previously reported.  However, we do recognize that no somatic mutations were 155 
detected even though this molecular panel has previously been reported to be relevant for CLL prognosis and 156 
treatment response [8].  Whether or not lacrimal sac involvement is associated with the same somatic gene 157 
mutations requires further evaluation.   158 
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